Home
ALNY
ALNY News

Latest Alnylam Pharmaceuticals Inc. (ALNY) News on July 27, 2024

Alnylam Pharmaceuticals (ALNY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Zacks

a day ago

Alnylam Pharmaceuticals (ALNY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Market Sentiment Around Loss-Making Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Simply Wall St.

4 days ago

Market Sentiment Around Loss-Making Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results

Business Wire

9 days ago

Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results

MT Newswires

12 days ago

Alnylam Pharmaceuticals Insider Sold Shares Worth $1,851,273, According to a Recent SEC Filing

Alnylam Pharmaceuticals (NASDAQ:ALNY) rallies 3.8% this week, taking five-year gains to 246%

Simply Wall St.

13 days ago

Alnylam Pharmaceuticals (NASDAQ:ALNY) rallies 3.8% this week, taking five-year gains to 246%

Alnylam Pharmaceuticals And Two More Value Stocks On US Exchange Estimated To Be Trading Below Intrinsic Value

Simply Wall St.

17 days ago

Alnylam Pharmaceuticals And Two More Value Stocks On US Exchange Estimated To Be Trading Below Intrinsic Value

Pipeline Moves: Alnylam’s Amvuttra approval prospects up after Phase III win

Clinical Trials Arena

19 days ago

Pipeline Moves: Alnylam’s Amvuttra approval prospects up after Phase III win

Baillie Gifford's Strategic Reduction in Alnylam Pharmaceuticals Holdings

GuruFocus.com

21 days ago

Baillie Gifford's Strategic Reduction in Alnylam Pharmaceuticals Holdings

An Intrinsic Calculation For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Suggests It's 50% Undervalued

Simply Wall St.

23 days ago

An Intrinsic Calculation For Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Suggests It's 50% Undervalued

MT Newswires

24 days ago

JPMorgan Chase Raises Price Target on Alnylam Pharmaceuticals to $248 From $160

Selling US$7.7m Of Alnylam Pharmaceuticals Stock Rewarded Insiders

Simply Wall St.

a month ago

Selling US$7.7m Of Alnylam Pharmaceuticals Stock Rewarded Insiders

MT Newswires

a month ago

UBS Adjusts Price Target on Alnylam Pharmaceuticals to $288 From $253, Maintains Buy Rating

Biotech Stock Roundup: ALNY Up on Study Success, ALIM on Merger News & Other Updates

Zacks

a month ago

Biotech Stock Roundup: ALNY Up on Study Success, ALIM on Merger News & Other Updates

MT Newswires

a month ago

Stifel Adjusts Price Target on Alnylam Pharmaceuticals to $295 From $215, Maintains Buy Rating

Argus Research

a month ago

Daily – Vickers Top Buyers & Sellers for 06/27/2024

MT Newswires

a month ago

RBC Raises Price Target on Alnylam Pharmaceuticals to $265 From $250, Keeps Outperform Rating

MT Newswires

a month ago

Alnylam Pharmaceuticals Insider Sold Shares Worth $370,747, According to a Recent SEC Filing

MT Newswires

a month ago

Alnylam Pharmaceuticals Insider Sold Shares Worth $1,917,475, According to a Recent SEC Filing

MT Newswires

a month ago

Alnylam Pharmaceuticals Insider Sold Shares Worth $485,773, According to a Recent SEC Filing

MT Newswires

a month ago

Alnylam Pharmaceuticals Insider Sold Shares Worth $7,161,360, According to a Recent SEC Filing

Morningstar Research

a month ago

Analyst Report: Alnylam Pharmaceuticals, Inc.

MT Newswires

a month ago

Sector Update: Health Care Stocks Ease Late Afternoon

MT Newswires

a month ago

Update: Alnylam Pharmaceuticals Shares Rise as Heart Disease Candidate Meets Primary Endpoint in Late-Stage Study

MT Newswires

a month ago

TD Cowen Adjusts Price Target on Alnylam Pharmaceuticals to $282 From $260, Maintains Buy Rating

MT Newswires

a month ago

Barclays Raises Price Target on Alnylam Pharmaceuticals to $291 From $236, Maintains Overweight Rating

MT Newswires

a month ago

Wells Fargo Raises Price Target on Alnylam Pharmaceuticals to $207 From $161, Maintains Equalweight Rating

Alnylam (ALNY) Soars as Heart Disease Drug Study Meets Goals

Zacks

a month ago

Alnylam (ALNY) Soars as Heart Disease Drug Study Meets Goals

MT Newswires

a month ago

Morgan Stanley Raises Alnylam Pharmaceuticals Price Target to $250 From $164, Maintains Equal Weight Rating

MT Newswires

a month ago

Evercore ISI Boosts Price Target on Alnylam Pharmaceuticals to $260 From $210, Keeps Outperform Rating

Top Three US Stocks Estimated Below Intrinsic Value In June 2024

Simply Wall St.

a month ago

Top Three US Stocks Estimated Below Intrinsic Value In June 2024

MT Newswires

a month ago

Chardan Raises Price Target on Alnylam Pharmaceuticals to $265 From $225, Keeps Buy Rating

MT Newswires

a month ago

RBC Raises Price Target on Alnylam Pharmaceuticals to $250 From $235, Keeps Outperform Rating

Morningstar Research

a month ago

Analyst Report: Alnylam Pharmaceuticals, Inc.

MT Newswires

a month ago

Sector Update: Health Care Stocks Rise in Late Afternoon Trading

Alnylam Soars on Positive Heart-Drug Data

The Wall Street Journal

a month ago

Alnylam Soars on Positive Heart-Drug Data

MT Newswires

a month ago

Top Midday Gainers

US Treasury Secretary Janet Yellen speaks to Yahoo Finance

Yahoo Finance Video

a month ago

US Treasury Secretary Janet Yellen speaks to Yahoo Finance

Associated Press Finance

a month ago

RXO, Alnylam Pharmaceuticals rise; ResMed, Sonoco Products fall, Monday, 6/24/2024

Alnylam reveals positive Phase III results for rare heart disease drug vutrisiran

Pharmaceutical Technology

a month ago

Alnylam reveals positive Phase III results for rare heart disease drug vutrisiran

Tech sector growth, EU considers fining Apple: Morning Brief

Yahoo Finance Video

a month ago

Tech sector growth, EU considers fining Apple: Morning Brief

Alnylam Stock Pops on Surprising Results From a Key Heart Disease Drug

Barrons.com

a month ago

Alnylam Stock Pops on Surprising Results From a Key Heart Disease Drug

Alnylam Stock Soars After Positive Results From Heart Disease Study

Barrons.com

a month ago

Alnylam Stock Soars After Positive Results From Heart Disease Study

MT Newswires

a month ago

Alnylam Pharmaceuticals Says Heart Disease Therapy Meets Primary Endpoint in Late-Stage Study

Alnylam Soars After Drug Meets Goal in Heart Disease Trial

Bloomberg

a month ago

Alnylam Soars After Drug Meets Goal in Heart Disease Trial

Alnylam Skyrockets After Hitting A 'Best-Case Scenario' For Heart Drug

Investor's Business Daily

a month ago

Alnylam Skyrockets After Hitting A 'Best-Case Scenario' For Heart Drug

Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations

Business Wire

a month ago

Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations

Alnylam (ALNY) Soars 5.3%: Is Further Upside Left in the Stock?

Zacks

a month ago

Alnylam (ALNY) Soars 5.3%: Is Further Upside Left in the Stock?

Alnylam says heart drug succeeds in closely watched study

BioPharma Dive

a month ago

Alnylam says heart drug succeeds in closely watched study

Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Shift From Loss To Profit

Simply Wall St.

a month ago

Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Shift From Loss To Profit

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus

GlobeNewswire

2 months ago

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus

Share buy-back programme - week 23

GlobeNewswire

2 months ago

Share buy-back programme - week 23

Japan's service sector mood hits nearly 2-year low in May

Reuters

2 months ago

Japan's service sector mood hits nearly 2-year low in May

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share

GlobeNewswire

2 months ago

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share

Enduring role of 'treasuring the past' hailed

PR Newswire

2 months ago

Enduring role of 'treasuring the past' hailed

Virginie Leroy joins VINCI’s Executive Committee

GlobeNewswire

2 months ago

Virginie Leroy joins VINCI’s Executive Committee

Japan GDP: rebound hopes rise as number revised up

Reuters Videos

2 months ago

Japan GDP: rebound hopes rise as number revised up

Biophytis Announces Filing of an IND Application with the US FDA for its Phase 2 Study in Obesity

ACCESSWIRE

2 months ago

Biophytis Announces Filing of an IND Application with the US FDA for its Phase 2 Study in Obesity

MT Newswires

2 months ago

Alnylam Pharmaceuticals Insider Sold Shares Worth $3,224,546, According to a Recent SEC Filing

MT Newswires

3 months ago

HC Wainwright Adjusts Price Target on Alnylam Pharmaceuticals to $400 From $395, Maintains Buy Rating

Alnylam Issues 2023 Corporate Responsibility Report

Business Wire

3 months ago

Alnylam Issues 2023 Corporate Responsibility Report

The Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Simply Wall St.

3 months ago

The Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) First-Quarter Results Are Out And Analysts Have Published New Forecasts

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2024 Earnings Call Transcript

Insider Monkey

3 months ago

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2024 Earnings Call Transcript

Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y

Zacks

3 months ago

Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y

Morningstar Research

3 months ago

Analyst Report: Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals First Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

3 months ago

Alnylam Pharmaceuticals First Quarter 2024 Earnings: Beats Expectations

GuruFocus.com

3 months ago

Alnylam Pharmaceuticals Inc (ALNY) (Q1 2024) Earnings Call Transcript Highlights: Strong Growth ...

Decoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT Insight

GuruFocus.com

3 months ago

Decoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT Insight

Compared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at Key Metrics

Zacks

3 months ago

Compared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at Key Metrics

Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates

Zacks

3 months ago

Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates

MT Newswires

3 months ago

Alnylam Pharmaceuticals' Q1 Non-GAAP Net Loss Narrows as Revenue Increases; 2024 Outlook Affirmed

Associated Press Finance

3 months ago

Alnylam: Q1 Earnings Snapshot

Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity

Business Wire

3 months ago

Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity

Pfizer’s strong Vyndaqel sales draw attention to rare disease drug’s patent life

BioPharma Dive

3 months ago

Pfizer’s strong Vyndaqel sales draw attention to rare disease drug’s patent life

Gear Up for Alnylam (ALNY) Q1 Earnings: Wall Street Estimates for Key Metrics

Zacks

3 months ago

Gear Up for Alnylam (ALNY) Q1 Earnings: Wall Street Estimates for Key Metrics

Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia

CNW Group

3 months ago

Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia

Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks

3 months ago

Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results

Business Wire

3 months ago

Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results

Why Alnylam Pharmaceuticals (ALNY) Stock Might be a Great Pick

Zacks

4 months ago

Why Alnylam Pharmaceuticals (ALNY) Stock Might be a Great Pick

Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension

Business Wire

4 months ago

Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension

Those who invested in Alnylam Pharmaceuticals (NASDAQ:ALNY) five years ago are up 63%

Simply Wall St.

4 months ago

Those who invested in Alnylam Pharmaceuticals (NASDAQ:ALNY) five years ago are up 63%

Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session

Business Wire

4 months ago

Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session

30 Biggest Biotechnology Companies in the World

Insider Monkey

4 months ago

30 Biggest Biotechnology Companies in the World

Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease

Business Wire

4 months ago

Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease

Alnylam (ALNY), Roche's Blood Pressure Drug Meets Study Goal

Zacks

5 months ago

Alnylam (ALNY), Roche's Blood Pressure Drug Meets Study Goal

Reuters

5 months ago

Roche, Alnylam say blood pressure drug succeeds in mid-stage trial

Alnylam, Roche blood pressure drug scores in second mid-stage trial

BioPharma Dive

5 months ago

Alnylam, Roche blood pressure drug scores in second mid-stage trial

Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives

Business Wire

5 months ago

Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives

Alnylam to Webcast Presentations at Upcoming March Investor Conferences

Business Wire

5 months ago

Alnylam to Webcast Presentations at Upcoming March Investor Conferences

Morningstar Research

5 months ago

Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover

Morningstar Research

5 months ago

Analyst Report: Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals Full Year 2023 Earnings: In Line With Expectations

Simply Wall St.

5 months ago

Alnylam Pharmaceuticals Full Year 2023 Earnings: In Line With Expectations

Alnylam (ALNY) Q4 Loss Narrower Than Expected, Stock Dips 10%

Zacks

5 months ago

Alnylam (ALNY) Q4 Loss Narrower Than Expected, Stock Dips 10%

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q4 2023 Earnings Call Transcript

Insider Monkey

5 months ago

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q4 2023 Earnings Call Transcript

Thomson Reuters StreetEvents

5 months ago

Q4 2023 Alnylam Pharmaceuticals Inc Earnings Call

Decoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT Insight

GuruFocus.com

5 months ago

Decoding Alnylam Pharmaceuticals Inc (ALNY): A Strategic SWOT Insight

Why Alnylam Pharmaceuticals Stock Is Sinking Today

Motley Fool

5 months ago

Why Alnylam Pharmaceuticals Stock Is Sinking Today

Alnylam (ALNY) Reports Q4 Earnings: What Key Metrics Have to Say

Zacks

5 months ago

Alnylam (ALNY) Reports Q4 Earnings: What Key Metrics Have to Say

Alnylam Pharmaceuticals Inc (ALNY) Reports Strong Growth in 2023, Aiming for Continued Success ...

GuruFocus.com

5 months ago

Alnylam Pharmaceuticals Inc (ALNY) Reports Strong Growth in 2023, Aiming for Continued Success ...

Associated Press Finance

5 months ago

Alnylam: Q4 Earnings Snapshot

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity

Business Wire

5 months ago

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity

Share on Social Networks: